Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials

Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Kang, Minyong, Jeong, Chang Wook, Kwak, Cheol, Ku, Ja Hyeon, Kim, Hyeon Hoe
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Meta-Analysis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601768/
https://ncbi.nlm.nih.gov/pubmed/28938672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17741
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky